Laurentiu Nedelcu

Prof. Laurentiu Nedelcu


Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2016 in Journal of Gastrointestinal and Liver Diseases
Verified
Journal Article
Open access
TSTeodora Surdea-Blaga
Teodora Surdea-Blaga
ABAdriana Baban
Adriana Baban
LNLaurentiu Nedelcu
Laurentiu Nedelcu
DDDan L. Dumitrascu
Dan L. Dumitrascu
Irritable bowel syndrome (IBS) patients often present psychoform symptoms or psychiatric disorders. Among the psychological factors studied in IBS patients, two seem to influence mostly its severity: catastrophizing and somatization. Somatization is an independent risk factor for IBS. In addition, somatization more than the severity of IBS influences the way the patients perceive their illness, the outcome and the efficacy of treatment. Irritable bowel syndrome patients demonstrate greater catastrophizing scores than controls, and pain catastrophizing is a significant predictor of gastrointestinal symptoms related to pain. In this context we analysed the data regarding the efficacy of two psychological treatments in IBS: cognitive behavioral therapy and hypnosis. Cognitive behavioral therapy is focused on replacing maladaptive coping strategies with more positive cognitions and behaviors. Several studies showed that cognitive behavioral therapy is effective in reducing bowel symptoms in IBS, both post-treatment and short-term follow-up. Gut-directed hypnotherapy has beneficial short-term effects in improving gastrointestinal symptoms of patients with IBS, and the results are maintained after one year in half of the patients. Psychological treatments are a suitable option for selected IBS patients. Abbreviations: CBT: Cognitive Behavioral Therapy; FGIDs: functional gastrointestinal disorders; GDH: Gut-Directed Hypnotherapy; GI: gastrointestinal; HRQoL: health related quality of liffe; IBS: irritable bowel syndrome; ICBT: Internet-delivered CBT; ISM: Internet-delivered Stress Management; NNT: number needed to treat; PROs: Patient-reported outcomes; QoL: Quality of Life; SD: Somatization Disorders; SMT: Supportive Medical Treatment.

18 June 2021 in Journal of Gastrointestinal and Liver Diseases
Verified
Journal Article
Open access
PDF file
Dan L DumitrascuDan L Dumitrascu
Dan L Dumitrascu
ABAdriana Baban
Adriana Baban
IBIon Bancila
Ion Bancila
OBOana Bogdana Barboi
Oana Bogdana Barboi
SBSimona Maria Bataga
Simona Maria Bataga
VDVasile Drug
Vasile Drug
Background and Aims: The nonpharmacological therapy in irritable bowel syndrome (IBS) is expanding rapidly. Practitioners and medical educators need to be aware of progress and changes in knowledge of this topic. The Romanian Society of Neurogastroenterology aimed to create guidelines based on best evidence on the use of nonpharmacological therapy in IBS. Methods: A group of experts was constituted. This was divided in eleven subgroups dedicated to eleven categories of nonpharmacological therapy. The subgroups searched the literature and formulated statements and recommendations. These were submitted to vote in order to obtain consensus. Results: The outcome of this activity is represented by the guidelines of the Romanian Society of Neurogastroenterology, presented in this paper. The recommendations are seen as complementary to the pharmacological therapy and are not intended to recommend avoiding pharmacological drugs. Conclusions: These guidelines were elaborated by a Delphi process and represent a useful tool for physicians managing patients with IBS.

19 March 2022 in Journal of Gastrointestinal and Liver Diseases
Verified
Journal Article
Open access
PDF file
VDVasile Drug
Vasile Drug
SASabina Antonela Antoniu
Sabina Antonela Antoniu
OBOana Bogdana Barboi
Oana Bogdana Barboi
OAOana Cristina Arghir
Oana Cristina Arghir
IBIon Bancila
Ion Bancila
Dan L DumitrascuDan L Dumitrascu
Dan L Dumitrascu
Background and Aims: Gastroesophageal reflux disease (GERD) is a common condition present in daily practice with a wide range of clinical phenotypes. In this line, respiratory conditions may be associated with GERD. The Romanian Societies of Gastroenterology and Neurogastroenterology, in association with the Romanian Society of Pneumology, aimed to create a guideline regarding the epidemiology, diagnosis and treatment of respiratory conditions associated with GERD.Methods: Delphi methodology was used and eleven common working groups of experts were created. The experts reviewed the literature according to GRADE criteria and formulated 34 statements and recommendations. Consensus (>80% agreement) was reached for some of the statements after all participants voted.Results: All the statements and the literature review are presented in the paper, together with their correspondent grade of evidence and the voting results. Based on >80% voting agreement, a number of 22 recommendations were postulated regarding the diagnosis and treatment of GERD-induced respiratory symptoms. The experts considered that GERD may cause bronchial asthma and chronic cough in an important number of patients through micro-aspiration and vagal-mediated tracheobronchial reflex. GERD should be suspected in patients with asthma with suboptimal controlled or after exclusion of other causes, also in nocturnal refractory cough which needs gastroenterological investigations to confirm the diagnosis. Therapeutic test with double dose proton pump inhibitors (PPI) for 3 months is also useful. GERD induced respiratory conditions are difficult to treat; however,proton pump inhibitors and laparoscopic Nissen fundoplication are endorsed for therapy.Conclusions: This guideline could be useful for the multidisciplinary management of GERD with respiratory symptoms in current practice.

13 September 2024 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
DLDragos Lupu
Dragos Lupu
LNLaurentiu Nedelcu
Laurentiu Nedelcu
DTDiana Tint
Diana Tint
Background/Objectives: Cardiovascular involvement in severe cirrhosis presents diagnostic challenges and carries significant prognostic implications. This study aims to evaluate the relationship between liver disease severity and portal hypertension with the burden of diastolic dysfunction. Methods: We prospectively enrolled patients with hepatic cirrhosis, classified according to the Child–Pugh criteria. Of the 102 patients included, 65 were classified as Group A (non-severe cirrhosis: Child–Pugh Classes A and B) and 37 as Group B (severe cirrhosis: Child–Pugh Class C). Portal vein and spleen diameters were assessed using abdominal ultrasound. All patients underwent echocardiographic evaluation. LV systolic function was assessed by measuring ejection fraction, while diastolic function was evaluated using three parameters: E/Em ratio, E/Vp ratio, and indexed left atrial volume. Results: We observed a significantly greater burden of diastolic dysfunction in Group B compared to Group A. Specifically, the E/Vp ratio was 2.2 ± 0.4 in Group B versus 1.9 ± 0.3 in Group A (p < 0.001); the indexed LA volume was 34.5 ± 3.2 mL/m2 in Group B versus 30.1 ± 2.9 mL/m2 in Group A (p < 0.001); and the E/Em ratio was 17.0 ± 3.0 in Group B versus 11.5 ± 2.8 in Group A (p < 0.001). Additionally, the mean diameters of the portal vein and spleen were larger in Group B, with measurements of 14.3 ± 2.1 mm versus 11.5 ± 1.6 mm for the portal vein and 15.0 ± 1.2 mm versus 11.7 ± 1.5 mm for the spleen (p < 0.001), which correlated with the extent of diastolic dysfunction. Conclusions: Diastolic dysfunction was prevalent in 55% of patients with liver cirrhosis. The burden of diastolic dysfunction was higher in patients with severe hepatic cirrhosis compared to those with milder forms, and it correlated with the severity of portal hypertension, as assessed by measuring portal vein diameter and spleen diameter.

26 January 2021 in Experimental and Therapeutic Medicine
Verified
Journal Article
Closed access
PDF file
CGClaudia Mihaela Gavriș
Claudia Mihaela Gavriș
LNLaurentiu Nedelcu
Laurentiu Nedelcu
APAlina Mihaela Pascu
Alina Mihaela Pascu
Thirty‑five years after it was first described, antiphospholipid syndrome (APS) is unanimously recognized as a systemic autoimmune disease, a major acquired thrombophilia, which can affect any arterial or venous vascular territory, explaining the great diversity of clinical manifestations. The current classification criteria updated in the International Consensus Statement for Definite Antiphospholipid Syndrome from Sydney cannot explain alone the unpredictable evolution with thrombotic events of the patients diagnosed with APS. Although the link to genetics and epigenetics has not been clearly defined as in other autoimmune diseases, it is clear that a proper stratification of thrombotic risk in the era of personalized medicine must include classic biological markers (antiphospholipid antibodies, aPL), along with the already recognized phenotypes, non‑conventional serological markers, and additional genetic risk factors for thrombosis. Moreover, with advancing age, a patient with APS develops other thrombotic risk factors which include: hypertension and dyslipidemia among others. According to the classification criteria, a patient is considered to have a low, moderate or high thrombotic risk. In clinical practice, patients with the same risk score may have completely different evolutions in terms of the recurrence of thrombosis. Concerning this approach, it appears that new non‑conventional serological markers, phenotype‑assessment and genetic determinants have an increasing importance and should be reconsidered in a proper thrombotic risk evaluation in patients with APS, compared to the initial concept of APS as first defined.

30 July 2017 in Iranian Red Crescent Medical Journal
Verified
Journal Article
Open access
PDF file
LNLaurentiu Nedelcu
Laurentiu Nedelcu
TDTeodora Dumitrescu
Teodora Dumitrescu
Introduction: Gastrointestinal stromal tumors (GIST) represent less than 1% of all gastrointestinal tumors. The GIST diagnosis in a patient with a newly discovered myasthenia gravis (MG) raises the problem of evolution and treatment. Case Presentation: We present the case of a 58-year-old patient, who has been diagnosed with MG on December 2015 at emergency clinical county hospital Brasov, Romania. After further investigations, a localized gastric GIST was discovered. The treatment was surgical (January 2016) and the one-year evolution after the surgery was without relapse. Genetic mutations in the KIT and PDGFR genes were investigated. Conclusions: GIST may be accidentally discovered in asymptomatic patients. Genetic mutation examinations are needed in order to provide evidence. MG in association with GIST is rare and raises problems of diagnosis and treatment. Keywords: Gastrointestinal Stromal Tumors; Myasthenia Gravis; Mutations